A detailed history of New York State Common Retirement Fund transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 15,265 shares of TRVI stock, worth $64,723. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,265
Previous 15,265 -0.0%
Holding current value
$64,723
Previous $45,000 13.33%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$2.44 - $3.36 $505 - $695
207 Added 1.37%
15,265 $45,000
Q1 2024

May 07, 2024

SELL
$1.3 - $3.7 $28,137 - $80,082
-21,644 Reduced 58.97%
15,058 $52,000
Q4 2023

Feb 01, 2024

SELL
$1.06 - $2.05 $87 - $170
-83 Reduced 0.23%
36,702 $49,000
Q3 2023

Nov 07, 2023

BUY
$2.11 - $2.47 $1,023 - $1,197
485 Added 1.34%
36,785 $80,000
Q2 2023

Aug 07, 2023

BUY
$1.8 - $3.44 $65,340 - $124,872
36,300 New
36,300 $87,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.